Substance Use & Misuse
February 1, 2026
Kai-Uwe Lewandrowski, Kenneth Blum, Sergio Schmidt et al.
Since 2000, rates of suicide and opioid overdose have sharply increased. Approximately one-third of individuals with major depressive disorder (MDD) experience treatment-resistant depression (TRD), highlighting the urgent need for novel therapeutic approaches. This review synthesizes pivotal preclinical and clinical findings on low-dose ketamine's rapid antidepressant effects and examines...
Science academique
2026
Kenneth Blum, Kai-Uwe Lewandrowski, Morgan P Lorio et al.
The aim of this perspective article is to evaluate the potential of Psychedelics in the management of Alcohol Use Disorder (AUD) vis-a-vis pre-existing therapeutic modalities and to elucidate practical directions for policy in AUD Addiction medicine, supported by scientific evidence, while prioritizing safety and accessibility. We performed a narrative synthesis of past and current literature...
Brain Sci
November 4, 2025
A. Benjamin Srivastava, Mark S. Gold
The past two decades have seen the reemergence of research investigating the therapeutic potential of psychedelic drugs across neuropsychiatric illnesses. One condition, alcohol use disorder (AUD), is of relevance given the broad public health implications and both limited effectiveness and attrition associated with currently available treatments. While emerging research has suggested that the...
Brain Sci
September 28, 2025
Sabrina Correa Da Costa, Nicholas L. Bormann, Tyler Oesterle et al.
3 citations
Background: Substance use disorders (SUDs) are highly prevalent, affecting over 48.5 million Americans. Available treatments for SUD remain insufficient, and many patients do not respond to existing interventions despite adequate adherence to treatments. While novel therapies for SUD are urgently needed, the use of psychedelic drugs for the treatment of SUDs has shown promise. Objectives: This...
Brain Sciences
March 20, 2024
Muhammet Celik, Mark S. Gold, Brian S Fuehrlein
22 citations
Alcohol use disorder (AUD) is a significant contributor to morbidity and mortality in the United States. It contributes to over 140,000 annual deaths, to over 200 related diseases and health conditions globally, and accounts for 5.1% of the global disease burden. Despite its substantial impact, AUD remains undertreated, marked by a scarcity of approved medications. This paper explores the...
Frontiers in Public Health
January 25, 2024
Yu Kyung Lee, Mark S. Gold, Kenneth Blum et al.
45 citations
Opioid use disorder (OUD) is a major public health threat, contributing to morbidity and mortality from addiction, overdose, and related medical conditions. Despite our increasing knowledge about the pathophysiology and existing medical treatments of OUD, it has remained a relapsing and remitting disorder for decades, with rising deaths from overdoses, rather than declining. The COVID-19...
Journal of addiction psychiatry
2024
Gianni Martire, Daniel Sipple, David Baron et al.
341 citations
Borderline personality disorder (BPD) and post-traumatic stress disorder (PTSD) share overlapping neurobiological mechanisms particularly reward deficiency and stress-like anti-reward processes. And so, BPD may be reclassified as a "traumatic personality stress disorder" (TPSD) with ensuing common therapeutic strategies that may stabilize dopaminergic reward function such as...
Journal of the Neurological Sciences
September 15, 2022
Sabrina Correa Da Costa, Tyler Oesterle, Teresa A Rummans et al.
21 citations
Existing pharmacological treatments for psychiatric disorders have demonstrated limited efficacy, delayed onset of action, and significant burden of side effects. Recent findings from human studies with psychedelics have shown promise, demonstrating rapid and sustained clinical benefits of these compounds for a variety of psychiatric disorders. Classical psychedelics have a rich history and...
Addiction Biology
October 2, 2007
Firas Kobeissy, Jennifer A. Jeung, Matthew Warren et al.
47 citations
ABSTRACT Club drug abuse is a growing problem in the United States. Beyond addiction and toxicity are endocrine effects which are not well characterized. Specifically, the changes in appetite following exposure to drugs of abuse are an interesting but poorly understood phenomenon. Serum hormones such as leptin, ghrelin, growth hormone (GH), and neuropeptide‐Y (NP‐Y) are known to affect...
Acta neuropathologica
September 2007
Matthew W Warren, Stephen F Larner, Firas H Kobeissy et al.
Abuse of the club drugs Methamphetamine (Meth) and Ecstasy (MDMA) is an international problem. The seriousness of this problem is the result of what appears to be programmed cell death (PCD) occurring within the brain following their use. This follow up study focused on determining which cell types, neurons and/or glial cells, were affected in the brains of drug-injected rats. Two proteolytic...
Psychiatric Annals
March 1, 1994
Mark S. Gold
11 citations
Use of LSD, and hallucinogens in general, appears to be increasing, according to surveys of high school students.
JAMA
February 9, 1994
Mark S. Gold
12 citations
To the Editor. —We have recently presented data 1 from our annual survey of 522 328 junior and senior school students from schools across the United States. This anonymous questionnaire on the prevalence of drug use was administered to all junior and senior students attending home rooms in these schools in 1993, and results were compared with 1992. Hallucinogen use increased significantly ( P t...